ENDO 2026 (Endocrine Society Meeting)

Official event fundamentals (from provided website content)

• Event name: ENDO 2026
• Dates: (not available in the provided official website text)
• Venue: (not available in the provided official website text)
• City/Country: (not available in the provided official website text)
• Event website (reference): https://endo2026.endocrine.org/

Event overview

ENDO is the flagship annual meeting associated with the Endocrine Society. Based on the event’s established purpose within the endocrine research and clinical community, ENDO typically functions as a high-density scientific and clinical platform where research, translational science, and clinical practice intersect. For attendee-list and buyer-profiling research, this type of meeting usually attracts decision-makers from across pharma/biotech, medical devices, diagnostics, academic medicine, clinical research organizations, payers, and specialty health organizations—along with clinicians and scientists who influence evidence generation, prescribing behavior, and technology adoption.

1️⃣ Who attends (BUYERS / ATTENDEES)

ENDO is generally not only a “pure academic audience” event. While it heavily features endocrine clinicians, scientists, and researchers, the buyer-relevant audience typically includes organizations that fund, develop, test, market, and implement endocrine therapies and tools.

Primary attendee groups (buyer-relevant):

• Clinical decision influencers: Endocrinologists, diabetes specialists, endocrinology fellows, and clinical faculty who shape clinical pathways and adoption of therapies and diagnostics.
• Research leadership: Principal investigators, lab directors, translational researchers, and clinical trial leadership who influence study design and partner selection.
• Commercial buyers (industry): Business and medical-affairs leadership from pharma and biotech, plus device/diagnostics commercial and market access teams—often supporting congress objectives such as brand visibility, evidence dissemination, and partner networking.
• Clinical operations buyers: CRA/clinical operations leaders and clinical trial stakeholders from CROs and real-world evidence organizations.
• Provider and payer ecosystem: Specialty clinic leadership, hospital systems, and payer organizations focused on endocrine and metabolic care quality, outcomes, and reimbursement strategy.
• Education and guideline stakeholders: Organizations involved in continuing medical education (CME) and guideline development partnerships.

How we define “buyers” for list targeting: we focus on roles that either (a) sponsor and promote therapies/technologies in endocrine care, (b) manage evidence-generation pipelines (clinical trials/HEOR), (c) own market access and payer strategy, or (d) procure/implement endocrine-relevant diagnostics and devices for clinical use.

2️⃣ Where the show is happening + attendee geographic origin

The provided official website text does not include the venue city/country or the dates. Because we must not contradict the official source, we are leaving location-specific fields blank.

Expected geographic origin (industry-level expectation):

• Global professional mix: ENDO meetings typically draw an international community of endocrinology researchers and clinicians.
• Buyer concentration tends to be strongest where industry and research networks are mature: North America and Europe often have strong participation from pharma/biotech, CROs, and clinical research leadership.
• Specialty patient-care ecosystems drive international interest: companies investing in diabetes, metabolic health, endocrinology diagnostics, and endocrine devices commonly attend because the audience is clinically specialized.

What we recommend for targeting (without needing exact venue data): we structure buyer research by organization headquarters/major offices (not just attendance origin), because ENDO buyer decision-making often maps to global commercial, medical affairs, HEOR, clinical trials, and market access teams.

3️⃣ Audience reach (Local / National / Global)

ENDO’s audience is typically best categorized as global in reach, even if the event location is in a single city at one time. The buyer-relevant value is usually driven by international industry participation and the presence of decision-makers who network across regions.

4️⃣ Sample buyer company names (BUYERS ONLY) + websites

Below are buyer-oriented sample organizations that commonly align with endocrine care—including diabetes/metabolic therapy, endocrine diagnostics, and endocrine-related medical devices. We recommend validating which specific organizations are participating/sponsoring in ENDO 2026 once the official exhibitor/sponsor list is confirmed.

Priority approach (top targets to start): Novo Nordisk, Eli Lilly, Merck, Roche, Sanofi, and Dexcom. These represent the highest-likelihood “buyer density” for endocrine/metabolic therapy, diagnostics, medical evidence, and clinician-facing engagement.

5️⃣ Job profiles, industries & event type

Best job profiles to target:

• Director / Head of Medical Affairs (Diabetes, Endocrinology, Metabolic)
• Medical Scientific Liaison (MSL) – Endocrinology / Diabetes
• HEOR Director / Director of Outcomes Research / Market Access Director
• Clinical Trials Program Lead / Director, Clinical Operations
• Therapeutic Area Marketing Director / Brand Strategy Lead
• Clinical Evidence Lead (for diagnostics/devices)
• Scientific Partnerships Manager / Clinical Research Partnerships Lead
• Real-World Evidence (RWE) Lead / Director, RWE
• Regulatory Affairs Director (where applicable to pipeline strategy)
• Director, Clinical Education / CME Partnership Lead (where applicable)

Industries we would map for targeting (using the provided industry list):

• Pharmaceuticals
• Medical Devices
• Hospital & Health Care
• Biotechnology
• Market Research
• Health, Wellness & Fitness
• Research
• Information Technology & Services (only if the client sells clinical/health data platforms)
• Internet / Online Media (only if the client sells healthcare content or platforms)

Event type (buyer lens):

• Medical/scientific conference
• Clinical education + evidence exchange
• Therapeutic area networking (endocrinology, diabetes, metabolic health)
• Exhibits and partner engagement (pharma/biotech, devices, diagnostics, CRO/RWE)

6️⃣ Estimated attendance (expected total footfall)

The provided official website text does not include an attendee count. To avoid unreliable estimates, we are leaving the numeric footfall blank.

Practical guidance for buyer-data planning:

• Buyer density in ENDO-type meetings is driven by sponsor/exhibitor size and medical/scientific program participation (sessions, poster halls, networking events).
• For attendee-list research, buyer quality usually comes from narrowing to medical affairs, clinical operations, market access, HEOR, and clinical evidence roles rather than broad audience targeting.

7️⃣ Key focus areas & buyer engagement

Key focus areas (high-likelihood themes for endocrinology buyers):

• Diabetes and metabolic disease research (clinical trial updates, mechanisms, outcomes)
• Endocrine therapeutics (efficacy, safety, real-world adoption)
• Clinical evidence and guidelines alignment
• Diagnostics and clinical testing pathways
• Device-enabled care (where relevant: CGM/insulin delivery and clinical evidence)
• Health economics, outcomes, and market access
• Translational research and investigator collaboration

How we recommend buyers engage at this kind of meeting:

• Medical-scientific presence: posters, symposiums, investigator sessions, and MSL outreach
• Evidence strategy: HEOR/RWE presentations and partnerships for outcomes research
• Technology and diagnostics: clinical evidence narratives and adoption pathway discussions
• Partnership building: CRO/clinical operations and academic collaboration meetings

8️⃣ Client-product fit note (we need your client details to finalize the “best buyers”)

We can generate a highly accurate “best buyers” shortlist only after we review the client’s product and confirm who the buyer is (and what type of buying they do in the ecosystem). Please share:

• Client website URL
• What the client sells (1–2 sentences)
• Buyer type (e.g., pharma medical affairs, device clinical evidence, diagnostics lab director, CRO/clinical operations, payer/HEOR)
• Preferred geography (global, US-only, EU, etc.)

While we are waiting for the client website, here is the preliminary “best buyer fit” logic we would apply for ENDO 2026:

• If the client sells diabetes/endocrine therapies or medical evidence services → prioritize Pharma/Biotech medical affairs, HEOR, and clinical trials leadership (examples above: Novo Nordisk, Eli Lilly, Sanofi, Merck).
• If the client sells diagnostics or endocrine-related lab testing platforms → prioritize Diagnostics strategy, clinical evidence, and hospital purchasing/informatics teams (examples above: Roche, Abbott).
• If the client sells devices connected to endocrine care → prioritize diabetes care medical evidence and market access (examples above: Dexcom, Medtronic, Insulet).
• If the client sells clinical research enablement, CRO services, or RWE analytics → prioritize CRO business development, clinical operations, and RWE/HEOR (examples above: IQVIA, ICON).

Initial “best buyers to start with” for most endocrine-focused offers: Novo Nordisk, Eli Lilly, Merck, Roche, Sanofi, Dexcom, and IQVIA. This set usually captures both therapeutic evidence stakeholders and the technology/outcomes ecosystem.

9️⃣ Final recommendation (buyer-list targeting strategy)

ENDO 2026 is strong for buyer-focused prospecting because it concentrates high specialty stakeholders and makes it easier to reach decision-makers tied to endocrine/metabolic care. We recommend positioning our buyer research as a specialty endocrine business targeting package rather than a broad healthcare list, focusing on the highest-conversion roles: Medical Affairs, MSL/Clinical Evidence, HEOR/Market Access, Clinical Trials/Clinical Operations, and Therapeutic Area Marketing/Strategy.

Quality scoring (buyer relevance): 8/10 (specialty buyer density is typically high when targeting is role-based).

Next step we need from you

Please share the client website. Once we review it, we will return: (1) the most relevant industries from your provided list, (2) the top buyer titles to target, (3) a refined 15–20 buyer table specifically tailored to the client’s product category and ICP.